Back to top
more

OptimizeRx (OPRX)

(Delayed Data from NSDQ)

$20.88 USD

20.88
342,988

-0.80 (-3.69%)

Updated Oct 27, 2025 04:00 PM ET

After-Market: $20.26 -0.62 (-2.97%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 243)

Industry: Computer - Software

Zacks News

Zacks Equity Research

OptimizeRx Corp. (OPRX) is a Great Momentum Stock: Should You Buy?

Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Indrajit Bandyopadhyay headshot

OptimizeRx Bets on AI and Workflow Integration - Will This Pay Off?

OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.

Zacks Equity Research

Best Growth Stocks to Buy for September 5th

OPRX, KT and GLDD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 5, 2025.

Zacks Equity Research

Best Growth Stocks to Buy for September 3rd

OPRX, PHIN and KT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 3, 2025.

Zacks Equity Research

What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now?

Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy

OptimizeRx (OPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Best Momentum Stock to Buy for August 21st

OPRX, BZ and ANET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21, 2025.

Zacks Equity Research

OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates

OptimizeRx (OPRX) delivered earnings and revenue surprises of +700.00% and +30.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Shopify Q2 Earnings Beat Estimates, Revenues Jump Y/Y, Shares Rise

SHOP surges 22% after Q2 beats, fueled by strong GMV growth, rising merchant revenues, and upbeat Q3 guidance.

Zacks Equity Research

MKSI Q2 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Rise

MKS Instruments' second-quarter 2025 results reflect strong growth in the Semiconductor, and Electronics and Packaging markets.

Zacks Equity Research

Fastly Posts Narrower Loss in Q2 Earnings, Revenues Rise Y/Y

FSLY pops 10.6% pre-market as Q2 loss narrows and revenues jump 12.3%, topping estimates on both lines.

Zacks Equity Research

Best Growth Stocks to Buy for August 7th

WDC, OPRX and JBL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 7, 2025

Zacks Equity Research

Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates

Smith Micro Software (SMSI) delivered earnings and revenue surprises of -7.69% and -5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMD Q2 Earnings Beat Estimates, Revenues Up Y/Y, Shares Fall

Advanced Micro Devices' second-quarter 2025 performance benefits from strong data center and gaming growth, but shares slip on export-related setbacks.

Zacks Equity Research

Best Growth Stocks to Buy for August 5th

PRIM, OPRX and PAAS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 5, 2025

Zacks Equity Research

Best Growth Stocks to Buy for August 1st

OPRX, JBL and ADRNY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 1, 2025.

Brian Bolan headshot

Bull Of The Day: OptimizeRX (OPRX)

This stock is reporting earnings next week and posting positive operating margins is going to be key.

Indrajit Bandyopadhyay headshot

Does OptimizeRx Have a Moat in the Crowded HealthTech Space?

OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?

Zacks Equity Research

Blackbaud (BLKB) Q2 Earnings and Revenues Surpass Estimates

Blackbaud (BLKB) delivered earnings and revenue surprises of +15.24% and +1.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Santanu Roy  headshot

Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus

AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.

Indrajit Bandyopadhyay headshot

OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?

OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.

Zacks Equity Research

Best Growth Stocks to Buy for July 22nd

OPRX, ADRNY and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 22, 2025.

Indrajit Bandyopadhyay headshot

Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?

OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.

Indrajit Bandyopadhyay headshot

OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?

OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.

Zacks Equity Research

Synopsys (SNPS) Moves 3.6% Higher: Will This Strength Last?

Synopsys (SNPS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.